129 related articles for article (PubMed ID: 17303312)
1. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
[TBL] [Abstract][Full Text] [Related]
2. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
3. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
5. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.
Yu L; Shen HY; Coelho JE; Araújo IM; Huang QY; Day YJ; Rebola N; Canas PM; Rapp EK; Ferrara J; Taylor D; Müller CE; Linden J; Cunha RA; Chen JF
Ann Neurol; 2008 Mar; 63(3):338-46. PubMed ID: 18300283
[TBL] [Abstract][Full Text] [Related]
7. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
8. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
9. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.
Stone TW; Ceruti S; Abbracchio MP
Handb Exp Pharmacol; 2009; (193):535-87. PubMed ID: 19639293
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
Cipriani S; Bizzoco E; Gianfriddo M; Melani A; Vannucchi MG; Pedata F
Exp Neurol; 2008 Sep; 213(1):163-70. PubMed ID: 18586241
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
Chen JF; Sonsalla PK; Pedata F; Melani A; Domenici MR; Popoli P; Geiger J; Lopes LV; de Mendonça A
Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
[TBL] [Abstract][Full Text] [Related]
12. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease.
Popoli P; Blum D; Domenici MR; Burnouf S; Chern Y
Curr Pharm Des; 2008; 14(15):1500-11. PubMed ID: 18537673
[TBL] [Abstract][Full Text] [Related]
13. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.
Fan MM; Raymond LA
Prog Neurobiol; 2007 Apr; 81(5-6):272-93. PubMed ID: 17188796
[TBL] [Abstract][Full Text] [Related]
14. Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease.
D'Alimonte I; D'Auro M; Citraro R; Biagioni F; Jiang S; Nargi E; Buccella S; Di Iorio P; Giuliani P; Ballerini P; Caciagli F; Russo E; De Sarro G; Ciccarelli R
Eur J Neurosci; 2009 Sep; 30(6):1023-35. PubMed ID: 19723291
[TBL] [Abstract][Full Text] [Related]
15. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
[TBL] [Abstract][Full Text] [Related]
16. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
Melani A; Cipriani S; Vannucchi MG; Nosi D; Donati C; Bruni P; Giovannini MG; Pedata F
Brain; 2009 Jun; 132(Pt 6):1480-95. PubMed ID: 19359287
[TBL] [Abstract][Full Text] [Related]
17. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?
Kordower JH; Isacson O; Emerich DF
Exp Neurol; 1999 Sep; 159(1):4-20. PubMed ID: 10486171
[TBL] [Abstract][Full Text] [Related]
18. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease.
Tarditi A; Camurri A; Varani K; Borea PA; Woodman B; Bates G; Cattaneo E; Abbracchio MP
Neurobiol Dis; 2006 Jul; 23(1):44-53. PubMed ID: 16651003
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Pinna A; Pontis S; Borsini F; Morelli M
Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.
Browne SE
Ann N Y Acad Sci; 2008 Dec; 1147():358-82. PubMed ID: 19076457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
